Product Overview
GR258/Rabbit/Monoclonal
GeneBio’s recombinant rabbit antibody recognizes MDM2 (Murine Double Minute 2), a nuclear phosphoprotein that binds and inhibits transactivation by tumor protein p53. MDM2 inhibits p53 by blocking transcriptional activation domain, targeting p53 for ubiquitination and exporting to cytoplasm. As a result of this function, MDM2 can promote tumor formation by targeting tumor suppressor proteins for proteasomal degradation and also affects the cell cycle, apoptosis, and tumorigenesis through interactions with other proteins, including retinoblastoma 1 and ribosomal protein L5. Overexpression of MDM2 can result in excessive inactivation of tumor protein p53, diminishing its tumor suppressor function.
This protein Overexpression of MDM2 protein is detected in a variety of cancers, specifically it can be useful for the following:
MDM2 overexpression is common in atypical lipomatous tumor and well differentiated liposarcoma and dedifferentiated liposarcoma (MDM2+) versus tumors that mimic them such as benign adipose tumors (MDM2-). MDM2 can distinguish dedifferentiated liposarcoma (MDM2+) from poorly differentiated sarcomas (MDM2-).
MDM2 can distinguish low grade osteosarcoma and parosteal osteosarcoma (MDM2+) from benign fibrous and fibro-osseous lesions (MDM-).
MDM2 is frequently amplified in human sarcomas and less frequently in other tumor types.
MDM2 can distinguish low grade osteosarcoma and parosteal osteosarcoma (MDM2+) from benign fibrous and fibro-osseous lesions (MDM2-).
MDM2 and CDK4 coexpression in high grade osteosarcoma suggests progression from low grade osteosarcoma and expression is higher in dedifferentiated osteosarcomas.
